Leukotriene Receptor Antagonist Pranlukast Suppresses Eosinophil Infiltration and Cytokine Production in Human Nasal Mucosa of Perennial Allergic Rhinitis
Restricted accessResearch articleFirst published online November, 2003
Leukotriene Receptor Antagonist Pranlukast Suppresses Eosinophil Infiltration and Cytokine Production in Human Nasal Mucosa of Perennial Allergic Rhinitis
The purpose of this study was to investigate the influence of pranlukast on eosinophilic inflammation and cytokine production in human nasal mucosa. Twelve patients were treated with pranlukast, and samples were obtained from the nasal mucosa of the inferior turbinate. With respect to cell infiltration, a significant decrease was observed in the percentage of inflammatory cells (secreted eosinophil cationic protein [EG2] and neutrophil elastase) after treatment. The levels of cytokines and chemical mediators (interleukin [IL]–4, IL-5, RANTES [regulated on activation, normal T cell expressed and secreted], cysteinyl leukotrienes, IL-1β, tumor necrosis factor–α, and IL-8) assessed by enzyme-linked immunosorbent assay and enzyme immunoassay were significantly decreased. These results indicate that pranlukast decreased the levels of a majority of the cytokines in nasal mucosa, leading to improvement in subjective nasal symptoms. Furthermore, these results support the hypothesis that pranlukast exerts its therapeutic action primarily by blocking the leukotriene receptors on eosinophils.
ShawRJFitzharrisPCromwellOWardlawAJKayAB. Allergen-induced release of sulphidopeptide leukotrienes (SRS-A) and LTB4 in allergic rhinitis. Allergy1985; 40: 1–6.
BisgaardHOlssonPBendeM. Effect of leukotriene D4 on nasal mucosal blood flow, nasal airway resistance and nasal secretion in humans. Clin Allergy1986; 16: 289–97.
4.
LaitinenLALaitinenAHaahtelaTVilkkaVSpurBWLeeTH. Leukotriene E4 and granulocytic infiltration into asthmatic airways. Lancet1993; 341: 989–90.
5.
TakiFSuzukiRToriiKMatsumotoSTaniguchiHTakagiK. Reduction of the severity of bronchial hyperresponsiveness by the novel leukotriene antagonist 4-oxo-8-[4-(4-phenyl-butoxy)benzoylamino]-2-(tetrazol-5-yl)-4H-1-benzopyran hemihydrate. Arzneimittelforschung1994; 44: 330–3.
6.
TaniguchiYTamuraGHonmaM. The effect of an oral leukotriene antagonist, ONO-1078, on allergen-induced immediate bronchoconstriction in asthmatic subjects. J Allergy Clin Immunol1993; 92: 507–12.
7.
TomariSShimodaTKawanoT. Effects of pranlukast, a cysteinyl leukotriene receptor 1 antagonist, combined with inhaled beclomethasone in patients with moderate or severe asthma. Ann Allergy Asthma Immunol2001; 87: 156–61.
8.
ShirasakiHAsakuraKNaritaSKatauraA. The effect of a cysteinyl leukotriene antagonist, ONO-1078 (pranlukast) on agonist- and antigen-induced nasal microvascular leakage in guinea pigs. Rhinology1998; 36: 62–5.
9.
BensonMStrannegardILStrannegardOWennergrenG. Topical steroid treatment of allergic rhinitis decreases nasal fluid TH2 cytokines, eosinophils, eosinophil cationic protein, and IgE but has no significant effect on IFN-γ, IL-1β, TNF-α, or neutrophils. J Allergy Clin Immunol2000; 106: 307–12.
10.
RissoanMCSoumelisVKadowakiN. Reciprocal control of T helper cell and dendritic cell differentiation. Science1999; 283: 1183–6.
OkudaM. A survey of rhinitis in Japan and an evaluation of the treatment with sodium cromoglycate. Rhinology1982; 20: 63–72.
13.
NumataTKonnoAYamakoshiTHanazawaTTeradaNNagataH. Comparative role of peptide leukotrienes and histamine in the development of nasal mucosal swelling in nasal allergy. Ann Otol Rhinol Laryngol1999; 108: 467–73.
14.
OkudaMWataseTMezawaALiuCM. The role of leukotriene D4 in allergic rhinitis. Ann Allergy1988; 60: 537–40.
15.
MizutaniNNabeTImaiASakuraiHTakenakaHKohnoS. Markedly increased nasal blockage by intranasal leukotriene D4 in an experimental allergic rhinitis model: Contribution of dilated mucosal blood vessels. Jpn J Pharmacol2001; 86: 170–82.
16.
OkudaMKatauraATogawaK. Clinical evaluation of leukotriene antagonist: ONO-1078 (pranlukast hydrate), on perennial allergic rhinitis. A double-blind, comparative study with epinastine hydrochloride (phase III study) [in Japanese]. Otologia Fukuoka1998; 44: 47–72.
17.
PhilipGMalmstromKHampelFC. Montelukast for treating seasonal allergic rhinitis: A randomized, double-blind, placebo-controlled trial performed in the spring. Clin Exp Allergy2002; 32: 1020–8.
18.
PulleritsTPraksLRistiojaVLotvallJ. Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol2002; 109: 949–55.
19.
DonnellyALGlassMMinkwitzMCCasalaTB. The leukotriene D4—receptor antagonist, ICI 204,219, relieves symptoms of acute seasonal allergic rhinitis. Am J Respir Crit Care Med1995; 151: 1734–9.
20.
ShirasakiHKanaizumiEWatanabeK. Expression and localization of the cysteinyl leukotriene 1 receptor in human nasal mucosa. Clin Exp Allergy2002; 32: 1007–12.
21.
BruijnzeelPLRihsSBetzS. Eosinophilic granulocytes and their significance in allergic diseases [in German]. Schweiz Med Wochenschr1992; 122: 173–80.
22.
ThiviergeMDotyMJohnsonJStankovaJRola-PleszczynskiM. IL-5 up-regulates cysteinyl leukotriene 1 receptor expression in HL-60 cells differentiated into eosinophils. J Immunol2000; 165: 5221–6.
23.
BentleyAMMengQRobinsonDSHamidQKayABDurhamSR. Increases in activated T lymphocytes, eosinophils, and cytokine mRNA expression for interleukin-5 and granulocyte/macrophage colony-stimulating factor in bronchial biopsies after allergen inhalation challenge in atopic asthmatics. Am J Respir Cell Mol Biol1993; 8: 35–42.
24.
VengeP. Eosinophil activity in bronchial asthma. Allergy Proc1994; 15: 139–41.
25.
KitaHAbu-GhazalehRISurSGleichGJ. Eosinophil major basic protein induces degranulation and IL-8 production by human eosinophils. J Immunol1995; 154: 4749–58.
26.
BisgaardH. Pathophysiology of the cysteinyl leukotrienes and effects of leukotriene receptor antagonists in asthma. Allergy2001; 56(suppl 66): 7–11.
27.
NagataMSaitoKTsuchiyaKSakamotoY. Leukotriene D4 upregulates eosinophil adhesion via the cysteinyl leukotriene 1 receptor. J Allergy Clin Immunol2002; 109: 676–80.
28.
SpadaCSNievesALKraussAHWoodwardDF. Comparison of leukotriene B4 and D4 effects on human eosinophil and neutrophil motility in vitro. J Leukoc Biol1994; 55: 183–91.
29.
UnderwoodDCOsbornRRNewsholmeSJTorphyTJHayDW. Persistent airway eosinophilia after leukotriene (LT) D4 administration in the guinea pig: Modulation by the LTD4 receptor antagonist, pranlukast, or an interleukin-5 monoclonal antibody. Am J Respir Crit Care Med1996; 154: 850–7.
30.
HojoMSuzukiMMaghniKHamidQPowellWSMartinJG. Role of cysteinyl leukotrienes in CD4(+) T cell—driven late allergic airway responses. J Pharmacol Exp Ther2000; 293: 410–6.
31.
YoshidaSIshizakiYShojiT. Effect of pranlukast on bronchial inflammation in patients with asthma. Clin Exp Allergy2000; 30: 1008–14.
32.
PizzichiniELeffJAReissTF. Montelukast reduces airway eosinophilic inflammation in asthma: A randomized, controlled trial. Eur Respir J1999; 14: 12–8.
33.
TohdaYNakaharaHKuboHHaraguchiRFukuokaMNakajimaS. Effects of ONO-1078 (pranlukast) on cytokine production in peripheral blood mononuclear cells of patients with bronchial asthma. Clin Exp Allergy1999; 29: 1532–6.
34.
UnoTTanakaHNagaiH. Cysteinyl leukotrienes do not mediate lipopolysaccharide-induced airway hyperresponsiveness in guinea pigs. Prostaglandins1996; 52: 447–61.
35.
KnaniJCampbellAEnanderIPetersonCGBMichelFBBousquetJ. Indirect evidence of nasal inflammation assessed by titration of inflammatory mediators and enumeration of cells in nasal secretions of patients with chronic rhinitis. J Allergy Clin Immunol1992; 90: 880–9.
36.
CassatellaMA. The production of cytokines by polymorphonuclear neutrophils. Immunol Today1995; 16: 21–6.
37.
HaziotATsuberiBZGoyertSM. Neutrophil CD14: Biochemical properties and role in the secretion of tumor necrosis factor—alpha in response to lipopolysaccharide. J Immunol1993; 150: 5556–65.
38.
ShuteJ. Interleukin-8 is a potent eosinophil chemo-attractant. Clin Exp Allergy1994; 24: 203–6.
39.
SanzMJWegVBBolanowskiMANoursharghS. IL-1 is a potent inducer of eosinophil accumulation in rat skin. Inhibition of response by a platelet-activating factor antagonist and an anti-human IL-8 antibody. J Immunol1995; 154: 1364–73.
40.
HorieSGleichGJKitaH. Cytokines directly induce degranulation and superoxide production from human eosinophils. J Allergy Clin Immunol1996; 98: 371–81.
41.
GoddingVStarkJMSedgwickJBBusseWW. Adhesion of activated eosinophils to respiratory epithelial cells is enhanced by tumor necrosis factor—alpha and interleukin-1 beta. Am J Respir Cell Mol Biol1995; 13: 555–62.
IshizakaAHasegawaNSakamakiF. Effects of ONO-1078, a peptide leukotriene antagonist, on endotoxin-induced acute lung injury. Am J Respir Crit Care Med1994; 150: 1325–31.
